Fighting obesity made easy

The Central Marine Fisheries Research Institute (CMFRI) has commercialized its recently-developed nutraceutical product named CadalminTM Antihypercholesterolemic extract (CadalminTM ACE) for reducing obesity and cholesterol. The CMFRI gave the exclusive license to the VLCC, a leading Indian MNC in wellness and obesity management for using the technology for commercial production and marketing of the product.

Dr. A. Gopalakrishnan, director of CMFRI, signed a license agreement with Sundeep Ahuja, director of the VLCC Group and Dr. A. H. Zaidi, executive vice-president (R & D) of the firm. CMFRI developed the anti-obesity nutraceutical product using natural marine bioactive ingredients from selected seaweeds after years of intensive research and the product was found to be effective in combating dyslipidemia and obesity. (Dyslipidemia is an abnormal amount of lipids (e.g., triglycerides, cholesterol and/or fat phospholipids in the blood).

The bioactive principles contained in CadalminTM ACE inhibit various enzymes like hydroxymethyl glutaryl coenzyme, reductase and various target receptors, which are responsible for causing obesity and dyslipidemia.

According to Dr. Gopalakrishnan, CadalminTM ACE provides a unique blend of 100 per cent natural marine bioactive ingredients from selected seaweeds with an eco-friendly 'green technology', which is currently under patent. "The product has been proved to be devoid of any side effects following long-term oral administration of the tablets as established by detailed pre-clinical trials. The nutraceutical product is prepared from seaweeds, which are known for their extraordinary medicinal properties and are commonly available in the Indian coastal waters," he said.